The Korean Journal of Medicine

The Korean Association of Internal Medicine (대한내과학회)
권호 표지

Residual Cardiovascular Risk Remains Despite of Statin Treatment: Importance of High-Density Lipoprotein Cholesterol

스타틴 치료 후에도 남아있는 심혈관계 질환의 위험성: HDL-C의 중요성

  • Park, Yae-Min (Division of Cardiology, Gachon University Gil Hospital, Gachon University of Medicine and Science) ;
  • Koh, Kwang-Kon (Division of Cardiology, Gachon University Gil Hospital, Gachon University of Medicine and Science)
  • 박예민 (가천의과학대학교 길병원 심장내과) ;
  • 고광곤 (가천의과학대학교 길병원 심장내과)
  • Published : 2011.04.01
⟨ Previous Next ⟩

Abstract

Lowering low-density lipoprotein-cholesterol (LDL-C) is the primary target to prevent cardiovascular events in patients with dyslipidemia at high risk for cardiovascular disease. Many patients on statin therapy have initial or recurrent coronary heart disease events despite reductions in LDL-C. Indeed, 2/3 of patients on statin therapy suffer from residual risk. Low high-density lipoprotein-cholesterol (HDL-C) and high triglycerides levels are modifiable and important factors to resolve a residual risk. Especially, low serum levels of HDL-C (< 40 mg/dL for men, < 50 mg/dL for women) are highly prevalent and are recognized as an independent risk factor for cardiovascular morbidity (myocardial infarction, stroke, peripheral arterial disease, and restenosis after coronary stenting) and mortality. Thus, therapy focusing on raising HDL-C may be an important paradigm for treating and slowing progression of atherosclerosis, coronary heart disease, and co-morbid metabolic disorders. In this review, we discuss the importance of HDL-C based on experimental and large scaled clinical trials.

Keywords

References

  1. Toth PP. When high is low: raising low levels of high-density lipoprotein cholesterol. Curr Cardiol Rep 2008;10:488-496. https://doi.org/10.1007/s11886-008-0077-2
  2. O'Connell BJ, Genest J Jr. High-density lipoproteins and endothelial function. Circulation 2001;104:1978-1983. https://doi.org/10.1161/hc3901.096667
  3. Getz GS, Reardon CA. High-density lipoprotein function in regulating insulin secretion: possible relevance to metabolic syndrome. Arterioscler Thromb Vasc Biol 2010;30:1497-1499. https://doi.org/10.1161/ATVBAHA.110.210583
  4. Jafri H, Alsheikh-Ali AA, Karas RH. Baseline and on-treatment high-density lipoprotein cholesterol and the risk of cancer in randomized controlled trials of lipid-altering therapy. J Am Coll Cardiol 2010;55:2846-2854. https://doi.org/10.1016/j.jacc.2009.12.069
  5. Kannel WB. Status of risk factors and their consideration in antihypertensive therapy. Am J Cardiol 1987;59:A80-A90. https://doi.org/10.1016/0002-9149(87)90182-2
  6. Frick MH, Elo O, Haapa K, Heinonen OP, et al. Helsinki Heart Study: primary-prevention trial with gemfibrozil in middle-aged men with dyslipidemia: safety of treatment, changes in risk factors, and incidence of coronary heart disease. N Engl J Med 1987;317:1237-1245. https://doi.org/10.1056/NEJM198711123172001
  7. Rubins HB, Robins SJ, Collins D, et al. Gemfibrozil for the secondary prevention of coronary heart disease in men with low levels of high-density lipoprotein cholesterol: veterans Affairs High-Density Lipoprotein Cholesterol Intervention Trial Study Group. N Engl J Med 1999;341:410-418. https://doi.org/10.1056/NEJM199908053410604
  8. Barter P, Gotto AM, LaRosa JC, et al. HDL cholesterol, very low levels of LDL cholesterol, and cardiovascular events. N Engl J Med 2007;357:1301-1310. https://doi.org/10.1056/NEJMoa064278
  9. Sacks FM, Tonkin AM, Shepherd J, et al. Effect of pravastatin on coronary disease events in subgroups defined by coronary risk factors: the prospective pravastatin pooling project. Circulation 2000;102:1893-1900. https://doi.org/10.1161/01.CIR.102.16.1893
  10. 한국지질동맥경화학회. 이상지질혈증 치료지침 2판. 8-9
  11. Tonkin AM, Chen L. Effects of combination lipid therapy in the management of patients with type 2 diabetes mellitus in the action to control cardiovascular risk in diabetes (ACCORD) trial. Circulation 2010;122:850-852. https://doi.org/10.1161/CIRCULATIONAHA.110.960112
  12. Athyros VG, Papageorgiou AA, Athyrou VV, Demitriadis DS, Kontopoulos AG. Atorvastatin and micronized fenofibrate alone and in combination in type 2 diabetes with combined hyperlipidemia. Diabetes Care 2002;25:1198-1202. https://doi.org/10.2337/diacare.25.7.1198
  13. Chew EY, Ambrosius WT, Davis MD, et al. Effects of medical therapies on retinopathy progression in type 2 diabetes. N Engl J Med 2010;363:233-244. https://doi.org/10.1056/NEJMoa1001288
  14. Koh KK, Quon MJ, Han SH, et al. Additive beneficial effects of fenofibrate combined with atorvastatin in the treatment of combined hyperlipidemia. J Am Coll Cardiol 2005;45:1649-1653. https://doi.org/10.1016/j.jacc.2005.02.052
  15. Koh KK, Quon MJ, Rosenson RS, Chung WJ, Han SH. Vascular and metabolic effects of treatment of combined hyperlipidemia: focus on statins and fibrates. Int J Cardiol 2008;124:149-159. https://doi.org/10.1016/j.ijcard.2007.04.080
  16. Kim JA, Montagnani M, Koh KK, Quon MJ. Reciprocal relationships between insulin resistance and endothelial dysfunction: molecular and pathophysiological mechanisms. Circulation 2006;113:1888-1904. https://doi.org/10.1161/CIRCULATIONAHA.105.563213
  17. Taylor AJ, Sullenberger LE, Lee HJ, Lee JK, Grace KA. Arterial biology for the investigation of the treatment effects of reducing cholesterol (ARBITER) 2: a double-blind, placebo-controlled study of extended-release niacin on atherosclerosis progression in secondary prevention patients treated with statins. Circulation 2004;110:3512-3517. https://doi.org/10.1161/01.CIR.0000148955.19792.8D
  18. Villines TC, Stanek EJ, Devine PJ, et al. The ARBITER 6-HALTS trial (arterial biology for the investigation of the treatment effects of reducing cholesterol 6-HDL and LDL treatment strategies in atherosclerosis): final results and the impact of medication adherence, dose, and treatment duration. J Am Coll Cardiol 2010;55:2721-2726. https://doi.org/10.1016/j.jacc.2010.03.017
  19. Gordon DJ, Probstfield JL, Garrison RJ, et al. High-density lipoprotein cholesterol and cardiovascular disease. Four Prospective American Studies. Circulation 1989;79:8-15. https://doi.org/10.1161/01.CIR.79.1.8